Literature DB >> 15588737

Not so EEZE: the 'EDHF' antagonist 14, 15 epoxyeicosa-5(Z)-enoic acid has vasodilator properties in mesenteric arteries.

Louise S Harrington1, John R Falck, Jane A Mitchell.   

Abstract

P-450 metabolites, including the epoxyeicosatrienoic acids, are likely candidates for endothelial derived hyperpolarising factor (EDHF). In the present study, we confirm that the stable analogue 11-nonyloxyundec-8(Z)-enoic acid is a vasodilator of murine vessels. However, we also show that the 'epoxyeicosatrienoic acid receptor' antagonist 14,15 EEZE similarly dilates murine vessels contracted with U46619, prostaglandin F2alpha or methoxamine, but not with endothelin-1 or potassium. We suggest that 14,15 EEZE is a partial agonist for the epoxyeicosatrienoic acids/EDHF receptor. These results illustrate an important pharmacological property of this antagonists, which is being increasingly used to study the nature of EDHF.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15588737     DOI: 10.1016/j.ejphar.2004.09.062

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  7 in total

1.  Inhibition of smooth muscle proliferation by urea-based alkanoic acids via peroxisome proliferator-activated receptor alpha-dependent repression of cyclin D1.

Authors:  Valerie Y Ng; Christophe Morisseau; John R Falck; Bruce D Hammock; Deanna L Kroetz
Journal:  Arterioscler Thromb Vasc Biol       Date:  2006-08-17       Impact factor: 8.311

2.  Functional screening for G protein-coupled receptor targets of 14,15-epoxyeicosatrienoic acid.

Authors:  Xuehong Liu; Zu-Yuan Qian; Fuchun Xie; Wei Fan; Jonathan W Nelson; Xiangshu Xiao; Sanjiv Kaul; Anthony P Barnes; Nabil J Alkayed
Journal:  Prostaglandins Other Lipid Mediat       Date:  2016-09-17       Impact factor: 3.072

3.  Role of soluble epoxide hydrolase in postischemic recovery of heart contractile function.

Authors:  John M Seubert; Christopher J Sinal; Joan Graves; Laura M DeGraff; J Alyce Bradbury; Craig R Lee; Kerry Goralski; Michelle A Carey; Ayala Luria; John W Newman; Bruce D Hammock; John R Falck; Holly Roberts; Howard A Rockman; Elizabeth Murphy; Darryl C Zeldin
Journal:  Circ Res       Date:  2006-07-20       Impact factor: 17.367

4.  Effects of the selective EET antagonist, 14,15-EEZE, on cardioprotection produced by exogenous or endogenous EETs in the canine heart.

Authors:  Garrett J Gross; Kathryn M Gauthier; Jeannine Moore; John R Falck; Bruce D Hammock; William B Campbell; Kasem Nithipatikom
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-04-25       Impact factor: 4.733

5.  Soluble epoxide hydrolase gene deletion is protective against experimental cerebral ischemia.

Authors:  Wenri Zhang; Takashi Otsuka; Nobuo Sugo; Ardi Ardeshiri; Yazan K Alhadid; Jeffrey J Iliff; Andrea E DeBarber; Dennis R Koop; Nabil J Alkayed
Journal:  Stroke       Date:  2008-03-27       Impact factor: 7.914

6.  P450 Eicosanoids and Reactive Oxygen Species Interplay in Brain Injury and Neuroprotection.

Authors:  Xuehong Liu; Catherine M Davis; Nabil J Alkayed
Journal:  Antioxid Redox Signal       Date:  2017-04-20       Impact factor: 8.401

7.  Endogenous epoxygenases are modulators of monocyte/macrophage activity.

Authors:  Jonas Bystrom; Jessica A Wray; Mary C Sugden; Mark J Holness; Karen E Swales; Timothy D Warner; Matthew L Edin; Darryl C Zeldin; Derek W Gilroy; David Bishop-Bailey
Journal:  PLoS One       Date:  2011-10-19       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.